Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neovasc Inc. NVCN

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.


NDAQ:NVCN - Post by User

Comment by Farminch2on Apr 18, 2018 9:04pm
143 Views
Post# 27908378

RE:Possible upcoming milestones?

RE:Possible upcoming milestones?Their reducer is approved and on sale in some europeen countries, starting with Germany. That's their revenue source for the moment. It might be approved in some other countries in a near and mid term futur, good potential. Their 2nd product, TiaraII has more potential of revenu imo, It is on trial for FDA approval with something  like 100 patient treated with very positive results. It's all in written in Q3 2017 MD&A, which everyone should read before investing.

They use to have 100 mil shares outstanding but to clear the 121 million$ dept to CardiaQ they had to do a PP which changes everything. When all warrants will be exerciced there will be 1,5B shares. From that you need to eveluate the value of the company. So 0,10$ makes it 150mil MKTCap. the thing is, if you're not in the know of the company, you can't predict what market would be fair value. I doubt they can even know, all depends on approvals and if insurance would cover medical fees for the device on patients. We only know that around 4 millions people in the USA are in need of that device that would prevent them from dying or have a really crappy life.

MD&A also talk about possible reverse split. That would be crucial to meet Nasdaq requirement and probably also TSX. So my call is there will be a RS soon enough. But it's not that important, what you gamble on is the TiaraII potential, that's about it. The CEO state that in mid and long term, TiaraII will be their most important revenu source, but how much is it worth??

Is it safe to drop some cash at this price? My call is YES. But do your DD and stay alert, this stock has shown in the past that it can moves really quick up and down.


<< Previous
Bullboard Posts
Next >>